RESEARCH Open Access



Chromatin-wide and transcriptome profiling integration uncovers p38a MAPK as a global regulator of skeletal muscle differentiation

Jessica Segalés¹, Abul B. M. M. K. Islam², Roshan Kumar³, Qi-Cai Liu⁴, Pedro Sousa-Victor^{1,7}, F. Jeffrey Dilworth⁴, Esteban Ballestar⁵, Eusebio Perdiguero^{1*} and Pura Muñoz-Cánoves^{1,6*}

Abstract

Background: Extracellular stimuli induce gene expression responses through intracellular signaling mediators. The p38 signaling pathway is a paradigm of the mitogen-activated protein kinase (MAPK) family that, although originally identified as stress-response mediator, contributes to establishing stem cell differentiation fates. p38 α is central for induction of the differentiation fate of the skeletal muscle stem cells (satellite cells) through not fully characterized mechanisms.

Methods: To investigate the global gene transcription program regulated by p38 α during satellite cell differentiation (myogenesis), and to specifically address whether this regulation occurs through direct action of p38 α on gene promoters, we performed a combination of microarray gene expression and genome-wide binding analyses. For experimental robustness, two myogenic cellular systems with genetic and chemical loss of p38 α function were used: (1) satellite cells derived from mice with muscle-specific deletion of p38 α , and (2) the C2C12 murine myoblast cell line cultured in the absence or presence of the p38 α / β inhibitor SB203580. Analyses were performed at cell proliferation and early differentiation stages.

Results: We show that p38α binds to a large set of active promoters during the transition of myoblasts from proliferation to differentiation stages. p38α-bound promoters are enriched with binding motifs for several transcription factors, with Sp1, Tcf3/E47, Lef1, FoxO4, MyoD, and NFATc standing out in all experimental conditions. p38α association with chromatin correlates very well with high levels of transcription, in agreement with its classical function as an activator of myogenic differentiation. Interestingly, p38α also associates with genes repressed at the onset of differentiation, thus highlighting the relevance of p38-dependent chromatin regulation for transcriptional activation and repression during myogenesis.

Conclusions: These results uncover p38a association and function on chromatin at novel classes of target genes during skeletal muscle cell differentiation. This is consistent with this MAPK isoform being a transcriptional regulator.

^{*} Correspondence: eusebio.perdiguero@upf.edu; pura.munoz@upf.edu

1Department of Experimental and Health Sciences, Pompeu Fabra University
(UPF), CIBER on Neurodegenerative diseases (CIBERNED), Barcelona, Spain
Full list of author information is available at the end of the article



Page 2 of 15

Background

Cellular signaling is essential for the cells' ability to respond to the environment by integrating external cues to intracellular mediators and effectors. Activation of mitogen-activated protein kinases (MAPKs) constitutes a paradigm of intracellular signaling. p38, a subgroup of the MAPKs, was initially identified as a transducer of the response to inflammatory and environmental stress conditions. There are four p38 MAPKs in mammals: MAPK14 (p38 $_{\alpha}$), MAPK11 (p38 $_{\beta}$), MAPK12 (p38 $_{\gamma}$), and MAPK13 (p38 $_{\delta}$) [1, 2]. Activation of these MAPKs has also been associated with the differentiation capacity of several stem cell types. In particular, p38 plays an integral role in the fate decision of stem cells of the skeletal muscle lineage [3, 4]. Muscle stem cells (also called satellite cells), established early during development, are marked by the expression of the paired-box transcription factor Pax7, and have as principal mission sustaining skeletal muscle regeneration [5, 6]. When stimulated by an injury or disease, these normally quiescent stem cells are activated, begin to proliferate as myoblasts and, subsequently, they either exit the cell cycle, differentiate and fuse to form new fibers (or repair damaged ones), or self-renew to replenish the satellite cell pool. In vitro studies using cellular models (satellite cell-derived primary myoblasts or myoblast cell lines) that recapitulate the myogenic stages of the in vivo regeneration process, in combination with the chemical inhibitor of p38α/ p38β SB203580, have shown an active participation of the p38 MAPK pathway in each stage, with a principal function as a regulator of the myoblast proliferation-todifferentiation transition, by inducing cell cycle withdrawal and expression of muscle differentiation-specific genes [3, 4, 7–9].

Consistent with their kinase activity, several transcription factors can be directly phosphorylated by $p38\alpha/\beta$ MAPKs, including E47, the dimerization partner of the master myogenic regulatory factors (MRFs) of the MyoD family, and MEF2, a transcription factor cooperating with the MRFs in myogenic gene transcription; these phosphorylation events have a profound effect on gene expression as they modulate the activity of MyoD-E47 and MEF2 on muscle-specific promoters [3, 10-14]. Furthermore, by phosphorylating the chromatin-associated protein BAF60c, p38 α/β kinases contribute to the assembly of the myogenic transcriptosome on the chromatin of muscle loci by promoting the recruitment of SWI/SNF chromatin remodeling complex [15-17] and ASH2Lcontaining mixed-lineage leukemia (MLL) methyltransferase complex [18, 19]. Through phosphorylation, p38 α also recruits SNF2-related CBP activator protein (SRCAP) subunit p18 Hamlet to muscle loci, which is in turn required for H2A.Z accumulation and transcriptional activation [20]. p38α-mediated phosphorylation of Ezh2, the enzymatic subunit of polycomb repressor complex 2 (PRC2) also regulates the expression of Pax7, thus controlling the decision of satellite cells to proliferate or differentiate [21]. By contrast, p38y represses MyoD transcriptional activity by direct phosphorylation, via association with the H3K9 methyltransferase KMT1A, thereby also influencing this myogenic decision [22]. Thus, the p38 MAPK pathway can either activate or repress gene expression in satellite cells, depending on the engagement of specific p38 isoforms. Notably, in vitro studies using satellite cells lacking individual p38 family members showed that the four p38 isoforms are not completely redundant during myogenesis [7, 23, 24], and uncovered a predominant role of the p38α isoform in myogenic differentiation [7, 23, 24], with p38y signaling contributing to proliferation by preventing premature differentiation [22], whereas p38ß and p38ß appeared rather dispensable for these processes [7, 23]. Because muscle regeneration in vivo can proceed quite effectively in the absence of the p38y isoform [23], but is defective in the absence of p38α [25], p38α is indeed acknowledged as the master kinase for reprogramming gene expression during the proliferation-to-differentiation switch of satellite cells in vitro and in vivo.

Studies in yeast have shown that the p38 MAPK homolog, Hog1, activates transcription in response to osmotic stress by acting directly at chromatin [26, 27]. Likewise, mammalian p38 MAPK can bind to some stress-responsive loci upon exposure to several types of stresses, emphasizing that the association of the MAPK with target promoters can stimulate gene expression [28]. In skeletal myoblasts, p38a has also been found to bind certain muscle-specific genes such as myogenin, muscle creatine kinase, and myosin heavy chain during the process of myogenic differentiation [15, 21]. However, whether p38α can regulate gene transcription globally during myogenesis via direct action on gene promoters is unknown. Here, we assessed the genomewide enrichment of the p38α MAPK isoform, coupled to the $p38\alpha$ -dependent global gene expression program, during the switch of myogenic cells from proliferationto-differentiation stages. Our findings enlarge the picture of p38α MAPK as an important coordinator of myogenic gene expression through direct association to chromatin.

Methods

Cell culture

The C2C12 myoblast cell line was cultured at 37 °C in 5 % CO2 in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen) with 10 % fetal bovine serum (FBS) and supplemented with antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin (growth medium (GM)).

Satellite cells were obtained from p38 α -deficient and WT mouse muscles, as described in [7] and their

Page 3 of 15

myoblast progeny was maintained on collagen-coated dishes in Ham's F10 medium supplemented with 20 % FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 5 ng/ml bFGF (GM). These cells are referred to as satellite cells throughout the study. Experiments were performed by plating cells on Matrigel (BD Biosciences) Basement Membrane Matrix-coated dishes. To induce differentiation in both primary and C2C12 myoblasts, GM was replaced by differentiation medium (DM) (DMEM supplemented with 2 % horse serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin) at myoblast subconfluence. For p38 α / β MAPK inhibition studies, SB203580 was added directly to DM at a final concentration of 5 μ M.

Western blotting

Western blotting was performed as described previously [7]. Antibodies used were phospho-p38 (Thr180/Tyr182) (Cell Signaling 9211) and Tubulin (Sigma T-6199).

Immunofluorescence in C2C12 myoblasts

C2C12 cells were fixed in PFA 4 % for 10 min at room temperature, washed with PBS, and permeabilized with 0.5 % Triton X-100 in PBS during 10 min. Cells were incubated with blocking solution (10 % goat serum, 10 % BSA in PBS) for 1 h at room temperature and then overnight at 4 °C with p38 α antibody (Santa Cruz Biotechnology sc-535) diluted 1/50 in blocking solution. After three washes in PBS-Tween 0.025 %, cells were further incubated with goat anti-rabbit conjugated with Alexa-Fluor 488 (Invitrogen; 1/250) for 1 h. DAPI (1/1000) was used to label DNA, and the slides were mounted with Mowiol. Imaging was carried out with TCS-SPE confocal microscope (Leica) using LAS AF software.

RNA isolation, reverse transcription (RT), and quantitative PCR (qPCR)

Total RNA from proliferating and differentiating myoblasts was isolated with TriPure Isolation Reagent and quantified with Nanodrop. M-MLV reverse transcriptase (Promega) was used to synthesize cDNAs from the total RNA (1 μ g) following the manufacturer's recommendations. RT-qPCR reactions were performed with SYBR Green in 384-well plates using the Roche LC-480 cycler (Roche Applied Science). The mRNA expression of target genes was normalized to L7 expression, and the data are represented as the mean \pm SD of three independent experiments. Primer sequences are listed in Additional file 1: Table S2.

Chromatin immunoprecipitation (ChIP) assay

ChIP assays were performed from approximately 5*10⁶ C2C12 cells per experiment. Briefly, cells were cross-

linked with 1 % formaldehyde for 10 min at room temperature, and the crosslinking was then quenched with 0.125 M glycine for 5 min. Cross-linked cells were washed twice with cold PBS, resuspended in 600 µl of SDS lysis buffer (1 % SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, plus protease inhibitors) and incubated on ice for 10 min. Cell lysate was sonicated to shear chromatin to an average length of 200-500 bp using a Diagenode Bioruptor. Sonicated samples were centrifuged at 13,000 rpm for 10 min and the chromatin concentration of the supernatant was quantified. Seventy microgram of chromatin were diluted 10-fold in ChIP dilution buffer (0.01 % SDS, 1.1 % Triton X-100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.1, plus protease inhibitors) and immunoprecipitated overnight at 4 °C with 3 μg of p38 α antibody (Cell Signaling 9218) and 1 μg of MyoD and Mef2 antibodies (Santa Cruz Biotechnology sc-304 and sc-13917, respectively) or control IgG antibody (Cell Signaling 2729). Twenty microliter of Magna ChIP Protein A + G Magnetic Beads (Millipore) were added and incubated for 1 h at 4 °C. Beads were successively washed with 1 ml of different buffers: lowsalt immune complex wash buffer (0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), high-salt immune complex wash buffer (0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), LiCl immune complex wash buffer (0.25 M LiCl, 1 % NP40, 1 % deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1), and TE (1 mM EDTA, 10 mM Tris-HCl, pH 8.0). To elute the immunocomplexes, beads were incubated twice in elution buffer (1 % SDS, 100 mM NaHCO3) for 15 min at room temperature. The crosslinking was reverted by further incubating the DNA at 65 °C overnight. DNA was extracted with phenol/chloroform, ethanol-precipitated and resuspended in 80 µl of H₂O for further analysis. Bound fraction and input were analyzed by PCR and qPCR using specific primer sets for each of the analyzed promoters (see Additional file 1: Table S2). Relative recruitment is calculated as the amount of amplified DNA normalized to input and relative to values from control IgG immunoprecipitation, which were set as 1 in each calculation.

Microarray analysis

RNA samples were collected from C2C12 cells (proliferating and differentiated for 24 h \pm the p38 α/β inhibitor SB203580) and primary myoblasts from WT and p38 α -deficient mice in proliferation conditions and at 24 h of differentiation. Transcriptome analysis was performed using the 44K Whole-Mouse Genome (Agilent), and the RNA labeling and hybridization process was performed following the manufacturer's instructions. Microarray analysis was performed with three samples per condition; for

Page 4 of 15

the primary myoblasts, each sample was a pool of three independent cultures. Moreover, and to avoid bias labeling artifacts, dye swap experiments were performed. Fluorescent images were obtained with an Agilent G2565BA scanner. Microarray images were quantified using Gene-Pix software. Only spots with signal intensities twice above the local background, not saturated, and not flagged by GenePix were considered reliable and used for subsequent analysis. Extracted intensities were subtracted from the local background, and the log2 ratios were normalized in an intensity-dependent fashion by global LOWESS. For normalization and differential expression analysis, we used [29] Bioconductor (www.bioconductor.org) LIMMA [27] for Agilent two-color microarray data. For differential expression analysis, we filtered for genes that show at least Log2FC 0.25 (≥+0.25 for upregulation and ≤ -0.25 for downregulation).

ChIP-on-chip analysis

Chromatin immunoprecipitation was performed in quadruplicate from independent C2C12 cultures of each condition. Each sample was cross-linked, and immunoprecipitation was performed as described above using p38α-specific antibodies (Cell Signaling). To avoid the high variability detected with p38a antibody, immunoprecipitated and input DNA were pooled, labeled by ligation-mediated PCR with Cy5 and Cy3 fluorescent dyes, respectively. Pools of labeled DNA were hybridized to a 244K Mouse Promoter Chip (Agilent) following the manufacturer's instructions. The array was scanned and analyzed with GenePix software as explained above. Genome-wide location data were normalized, and the ratio of immunoprecipitated to input DNA was determined for each probe. For each array, a confidence value (P value) was calculated for each probe using an error model as explained before [27]. Briefly, probes that scored significantly above background were then combined into probe sets of three probes if they passed the following filter: the center probe in the probe set has a single point *P* value <0.001, one of the flanking probes has a single point P value <0.01, and the three probes combined have a P value <0.001. For binding peaks that typically span over transcribed regions and thus span over several probes, the following filter was used: the center probe in the probe set has a single point P value <0.005, the three probes combined have a P value <0.0001 and one of the flanking probes has a combined P value <0.001. Bound probe sets that overlapped were collapsed into bound regions. For each bound region, the closest ORF was then assigned and the maximum ChIP enrichment identified (see Additional file 2: Table S1).

Bioinformatic and statistical analysis

Gene ontology analysis was performed using DAVID functional annotation clustering [30]. Gene set enrichment

analysis (GSEA) was performed using the default parameters [31]. Venn diagrams were generated using The BEG Ugent tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). Volcano plots of gene expression and statistical analysis data were performed using Graphpad Prism software. Quantitative data displayed as histograms are expressed as means \pm standard error of the mean (represented as error bars). Results from each group were averaged and used to calculate descriptive statistics. Mann—Whitney U test (independent samples) was used for pairwise comparisons among groups at each time point. Statistical significance was set at a P value <0.05.


Mice

Mice carrying the floxed p38 α , allele were generated by Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, USA). Floxed p38 α mice were crossed to More-CRE knock-in mice to obtain p38 α knockout mice. All animal experiments and isolation of satellite cells from wild type and knockout mice [7] were approved by the ethics committee of the Barcelona Biomedical Research Park (PRBB) and by the Catalan Government and used sex-, age- and weight matched littermate animals.

Results

Consequences of genetic and chemical p38a inhibition on the gene expression program of differentiating myoblasts Because p38α controls the transition of myoblasts from proliferating to differentiating stages, we aimed to study specifically the changes in gene expression occurring during this transition (Fig. 1a). To increase the robustness of the experimental strategy, we used distinct myogenic cellular models and p38α-inhibiting alternatives: satellite cells obtained from muscle of wild type (WT) mice or mice with deletion in p38α [7], and the C2C12 myoblast cell line, cultured in the absence or presence of the p38 α/β inhibitor SB203580 (SB) (Fig. 1a). Because the p38β isoform is not (or lowly) expressed in C2C12 myoblasts (Additional file 3: Figure S1), the inhibitory action of SB203580 on these cells will likely be attributable to p38α. Genome-wide microarrays of both types of cells (with/without genomic or chemical p38α-inhibitory conditions) in proliferation (growth medium (GM)) and early differentiation (24 h in differentiation medium (DM)) states were performed.

Through these analyses, we identified a large number of genes regulated by $p38\alpha$ (Fig. 1b; Additional file 2: Table S1), being this regulation particularly marked at the early 24 h myoblast differentiation stage. Gene ontology (GO) analysis using DAVID functional annotation clustering of the GO terms showed a downregulation in expression of muscle-differentiation-specific genes for satellite cells lacking $p38\alpha$, whereas genes involved in proliferation and cell-cycle progression were upregulated



(See figure on previous page.)

Fig. 1 Gene expression analysis of p38α-deficient satellite cells and C2C12 cells treated with SB203580 (SB). a Satellite cells and C2C12 myoblasts were cultured in growth medium (GM) until subconfluent and then shifted to differentiation medium (DM) at the indicated time points. (left) Representative pictures of WT and p38α-deficient satellite cells 24 and 48 h in DM, and relative expression levels of differentiation-specific genes Myog and Myh1 analyzed by qPCR. (right) Activation of p38 was analyzed in both cells types by Western Blot using an anti-phospho-p38 antibody and expression of p38a in satellite cells derived from WT, and p38a-deficient mice was analyzed by qPCR (right panel). **b** Volcano plot showing differentially expressed genes in p38a-deficient versus WT satellite cells in GM, and DM for 24 h (top and middle panel, respectively) and in SB-treated C2C12 cells versus untreated (bottom panel). Downregulated and upregulated genes are marked in green and red, respectively. c Gene ontology (GO) analysis of differentially expressed genes in p38a-deficient satellite cells over WT at 24 h DM was performed using DAVID. Enriched GO annotations of downregulated and upregulated genes are shown in green and red, respectively, **d** As in (**c**) GO analysis of differentially expressed genes in C2C12 myoblasts (SB-treated versus untreated) at 24 h in DM. e Non-proportional 2-way Venn diagram comparing the effect in gene expression of p38adeficient satellite cells at 24 h in DM (over WT) with the effect of chemical inhibition of p38a in C2C12 cells (SB treated over untreated). Only 102 and 169 genes are commonly upregulated and downregulated, respectively. f As in (d) GO analysis of genes that are commonly upregulated and downregulated in both C2C12 cells treated or not with SB and in satellite cells after 24 h in DM. g Comparison between expression arrays performed in C2C12 cells treated with SB203580 at 24 and 48 h in DM. The non-proportional 2-way Venn diagrams show the number of upregulated and downregulated genes in C2C12 cells treated with SB203580 over untreated cells. h Comparison between expression arrays performed in C2C12 cells treated with SB203580 (24 and 48 h DM) and p38α-deficient satellite cells

(Fig. 1c). p38α signaling in satellite cells also appeared to regulate multiple genes and transcription factors that had not been previously related to myogenesis, for example, genes encoding signaling proteins and genes involved in proteolysis or DNA metabolism and damage. In contrast, SB treatment of C2C12 cells caused downregulation of genes related to secretory pathways and cytoskeleton organization, whereas the expression of genes related to transcription, chromatin organization, or ion binding was upregulated (Fig. 1d). Of note, the cellcycle-related genes that were found upregulated in p38α-deficient satellite cells after 24 h in DM remained unchanged in SB-treated C2C12 cells at the same time point; however, SB-treated C2C12 cells showed upregulation of these proliferationrelated genes at a later time point in DM (i.e., 48 h), according to the recently published data [8], suggesting a delay in the cell-cycle exit of C2C12 immortalized myoblasts, compared to primary satellite cells, in differentiation-promoting conditions. Of the p38αregulated genes in both experimental conditions, only 102 and 169 genes were commonly up- and downregulated, respectively, in SB-treated C2C12 myoblasts and $p38\alpha$ -deficient satellite cells (Fig. 1e). Thus, the stringency imposed by the use of distinct muscle cell models and p38-inhibiting strategies allowed the identification of a robust list of bona fide genes dependent on p38α at the onset of myogenic differentiation (Additional file 2: Table S1). GO analysis of genes commonly regulated in SB-treated C2C12 cells, and p38α-deficient satellite cells at 24 h DM showed that the expression of muscle differentiation-specific genes is commonly downregulated in both types of cells in the absence of $p38\alpha$ signaling (Fig. 1f). In contrast, genes commonly upregulated in both conditions were related to the transcription and cell motion processes (Fig. 1f).

A further comparison of the expression arrays from C2C12 myoblasts in DM for 24 and 48 h (in the absence or presence of SB) revealed a dramatic difference in both time points: only 20 % of the genes upregulated by the 48 h DM + SB treatment were also upregulated at the earlier DM + SB 24 h time point (Fig. 1g); likewise, only 30 % of the downregulated genes at the 48 h DM + SB treatment were common with the 24 h DM + SB conditions. Thus, $p38\alpha$ regulates the muscle differentiation gene program in C2C12 myoblasts with distinct kinetics (i.e., p38α-dependent early and late myogenic genes) (Fig. 1g). Interestingly, comparison of the 24 and 48 h DM + SB C2C12 cells with the 24 h DM p38α-deficient satellite cells demonstrated that, in addition to cell-cycle exit, the kinetics of the p38α-dependent proliferation-todifferentiation gene expression transition program differ between both cell types; indeed, this transition was faster in satellite cells, as shown by the similar number of common p38α-regulated genes in the 24 h-DM satellite-cell time point and in C2C12 cells at both time points (Fig. 1h). It is probable that the faster differentiation kinetics might be related to the more rapid and pronounced activation of p38 MAPK signaling in satellite cells than C2C12 cells in the GM to DM transit conditions (Fig. 1a).

We next performed qPCR analysis of p38 α -deficient and WT satellite cells (Fig. 2a) and C2C12 myoblasts-treated or not with SB-treated (Fig. 2b) to validate the gene expression microarray results. We confirmed that transcripts belonging to different gene networks are regulated by p38 α (in both genetic and chemical inhibitory settings), including muscle-specific and cell-cycle-regulatory genes, multiple transcription factors, and genes encoding signaling proteins.

In order to identify transcription factor binding sites of genes regulated by $p38\alpha$, we performed a gene set enrichment analysis (GSEA) in both types of cells and $p38\alpha$ -inhibitory conditions. The analysis showed that




Fig. 2 Validation of the p38α-dependent genes from expression arrays. **a** p38α-regulated genes were validated by qPCR in satellite cells derived from WT and p38α-deficient mouse muscles after 24 h in DM. **b** Genes regulated by chemical inhibition of p38α were validated by qPCR in differentiating C2C12 myoblasts (24 h DM) treated or not with SB. Different gene networks are regulated by p38α: muscle-specific and cell-cycle regulator genes, transcription factors, and genes encoding signaling proteins. Values are mean ± SEM of three independent experiments. Non-parametric Mann–Whitney *U* test was used for comparisons (*P* values < 0.05)

genes regulated by p38 α have enriched binding sites for different transcription factors, such as Sp1, Lef1, Tcf3/E47, FoxO4, Pax4, MyoD, or NFATc (Fig. 3), and most of them are common in all conditions analyzed (satellite cells 24 h DM, C2C12 24 h DM, and 48 h DM; upand downregulated). Interestingly, E2F-binding sites are enriched exclusively in p38 α -regulated genes in p38 α -deficient satellite cells at 24 h DM, and in C2C12 cells at 48 h (but not at 24 h) DM, consistent with the dysregulation of the cell-cycle/proliferation gene program.

Identification of $p38\alpha$ -chromatin binding sites at the myogenic proliferation-to-differentiation switch

To investigate whether p38 α regulates global gene transcription at the myoblast proliferation-to-differentiation transition by directly acting at chromatin, we investigated the association of p38 α to gene promoters in proliferating (GM) and early differentiating myoblasts (24 h DM) by ChIP-on-chip analysis using a p38 α -specific antibody. Following our transcriptome analysis, and to focus on the

early events of differentiation and p38α activation, we performed our analysis in C2C12 cells. The obtained ChIPon-chip data revealed that the binding of p38α is markedly enriched at many gene promoters both in proliferation and early differentiation stages, consistent with its localization in the nuclear compartment in these two conditions (Additional file 3: Figure S2). A stringent analysis unveiled 2268 p38α-bound genes in myoblasts in GM and 1434-bound genes in DM. We detected a high overlap between GM and DM as more than 1000 genes were bound by p38 α in both myogenic conditions (Fig. 4a). A general clustering analysis of genes bound by p38α in C2C12 cells identified genes that could be grouped in five clusters according to the pattern of binding along the promoter (Fig. 4b). Interestingly, cluster 1 included many transcription factors, developmental regulators, and muscle-related genes, whereas cluster 5 was enriched in protein transport, phosphorylation, and cell cycle-related genes. GO analysis revealed common p38αbound genes enriched in positive and negative regulators of transcription, Wnt signaling pathway, actin cytoskeleton

Lef1 (2) 264 8.29E-82 Lef1 (2) 75 2.74E-22 E2f (Tfbp1) 14 1.33E-11 Tcf3 (E12) 258 4.42E-57 Foxo4 73 5.87E-20 Lef1 (2) 27 9.20E-11 Foxo4 230 3.99E-56 Tcf3 (E12) (2) 81 6.16E-20 E2f4 12 2.29E-09 Maz.Myc 236 5.79E-52 Srebf1 31 7.92E-16 Sp1 38 3.61E-08 Myc (2) 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (13) 65 6.89E-40 Ap4 51 3.29E-13 Maz.Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz.Myc 64 6.17E-13 Nfili3 10 8.32E-07 E2f (Tfbp1) 64 1.8E-38 Maz.Myc 64 6.17E-13 Nfili3 10 8.32E-07 E2f (Tfbp1) 64 1.8E-38 Foxf2 37 3.82E-12 Sox9	Enriched transcription factor binding sites											
Sp1 338 5.32E-88 Sp1 104 1.46E-28 E2f (10) 15 5.81E-13 Lef1 (2) 264 8.29E-82 Lef1 (2) 75 2.74E-22 E2f (10) 15 5.81E-13 Foxo4 230 3.99E-56 Foxo4 73 5.87E-20 Lef1 (2) 27 9.20E-11 Foxo4 230 3.99E-56 Tcf3 (E12) (2) 81 6.16E-20 E2f4 12 2.29E-09 Maz.Myc 236 5.79E-52 Srebf1 31 7.92E-16 Sp1 38 3.61E-08 Mfatc 206 3.01E-48 Nfatc 62 2.03E-15 Tcf3 (E12) 34 5.51E-08 Myc 21 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (113) 65 6.89E-40 Ap4 51 3.29E-13 Maz.Myc 30 7.78E-07 E2f (17bp1) 64 1.8E-38 Maz.Myc 64 6.17E-13 Maz.Myc	Up P	rimaries 24	lh	·								
Lef1 (2) 264 8.29E-82 Lef1 (2) 75 2.74E-22 E2f (Tfbp1) 14 1.33E-11 Tcf3 (E12) 258 4.42E-57 Foxo4 73 5.87E-20 Lef1 (2) 27 9.20E-11 Foxo4 230 3.99E-56 Tcf3 (E12) (2) 81 6.16E-20 E2f4 12 2.29E-09 Maz.Myc 236 5.79E-52 Srebf1 31 7.92E-16 Sp1 38 3.61E-08 Myc (2) 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (13) 65 6.89E-40 Ap4 51 3.29E-13 Maz.Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz.Myc 64 6.17E-13 Nfili3 10 8.32E-07 E2f (Tfbp1) 64 1.8E-38 Maz.Myc 64 6.17E-13 Nfili3 10 8.32E-07 E2f (Tfbp1) 64 1.8E-38 Foxf2 37 3.82E-12 Sox9	Factor	Genes	p-value	Factor	Genes	p-value	Factor	Genes	p-value			
Tcf3 (E12) 258 4.42E-57 Foxo4 73 5.87E-20 Lef1 (2) 27 9.20E-11 Foxo4 230 3.99E-56 Tcf3 (E12) (2) 81 6.16E-20 E2f4 12 2.29E-09 Max/Myc 236 5.79E-52 Srebf1 31 7.92E-16 Sp1 38 3.61E-08 Nfatc 206 3.01E-48 Nfatc 62 2.03E-15 Tcf3 (E12) 34 5.51E-08 Myc (2) 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (13) 65 6.89E-40 Ap4 51 3.29E-13 Maz:Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfili3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Foxf2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26	Sp1	338	5.32E-88	Sp1	104	1.46E-28	E2f (10)	15	5.81E-13			
Foxo4 230 3.99E-56 Tcf3 (E12) (2) 81 6.16E-20 E2f4 12 2.29E-09 Maz:Myc 236 5.79E-52 Srebf1 31 7.92E-16 Sp1 38 3.61E-08 Nfatc 206 3.01E-48 Nfatc 62 2.03E-15 Tcf3 (E12) 34 5.51E-08 Myc (2) 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (13) 65 6.89E-40 Ap4 51 3.29E-13 Maz:Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfill3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Fox/2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Mfatc 26 2.26E-06 Fox/2 107 1.27E-27 Tcf8 33 2.3TE-11 Atf2 8 3.	Lef1 (2)	264	8.29E-82	Lef1 (2)	75	2.74E-22	E2f (Tfbp1)	14	1.33E-11			
Maz:Myc 236 5.79E-52 Srebf1 31 7.92E-16 Sp1 38 3.61E-08 Nfatc 206 3.01E-48 Nfatc 62 2.03E-15 Tcf3 (E12) 34 5.51E-08 Myc (2) 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (Tfbp1) 65 6.89E-40 Ap4 51 3.29E-13 Maz:Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfiil3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfiil3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Fox/2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26 2.26E-06 Fox/2 107 1.27E-27 Tcf8 33 2.3FE-11 Aff2 8 3	Tcf3 (E12)	258	4.42E-57	Foxo4	73	5.87E-20	Lef1 (2)	27	9.20E-11			
Nfatc 206 3.01E-48 Nfatc 62 2.03E-15 Tcf3 (E12) 34 5.51E-08 Myc (2) 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (13) 65 6.89E-40 Ap4 51 3.29E-13 Maz:Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfiil3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Foxf2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26 2.26E-06 Foxf2 107 1.27E-27 Tcf8 33 2.37E-11 Atf2 8 3.07E-06 Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Foxd2 16 1.34E-05	Foxo4	230	3.99E-56	Tcf3 (E12) (2)	81	6.16E-20	E2f4	12	2.29E-09			
Myc (2) 140 1.99E-43 Pax4 47 1.68E-13 Pax4 22 4.59E-07 E2f (13) 65 6.89E-40 Ap4 51 3.29E-13 Maz:Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfili3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Foxf2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26 2.26E-06 Foxf2 107 1.27E-27 Tcf8 33 2.37E-11 Aff2 8 3.07E-06 Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Fox1 90 8.16E-25 Ets2 38 1.11E-10 Fox04 26 9.92E-06 Dditt3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Foxf2 17 2.75E-05	Maz:Myc	236	5.79E-52	Srebf1	31	7.92E-16	Sp1	38	3.61E-08			
E2f (13) 65 6.89E-40 Ap4 51 3.29E-13 Maz:Myc 30 7.78E-07 E2f (Tfbp1) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfiil3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Foxf2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26 2.26E-06 Foxf2 107 1.27E-27 Tcf8 33 2.37E-11 Aff2 8 3.07E-06 Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Fox04 26 9.92E-06 Dditt3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Foxf2 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05	Nfatc	206	3.01E-48	Nfatc	62	2.03E-15	Tcf3 (E12)	34	5.51E-08			
E2f (Tfbp1) 64 1.8E-38 Maz:Myc 64 6.17E-13 Nfii3 10 8.32E-07 E2f (Tfbp2) 64 1.8E-38 Foxf2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26 2.26E-06 Foxf2 107 1.27E-27 Tcf8 33 2.37E-11 Aff2 8 3.07E-06 Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Foxo4 26 9.92E-06 Ddit3 (Chop) 50 1.03E-24 Aff3 25 7.25E-10 Foxf2 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 CEBPa 50 1.03E-24 Ipf1 17 2.72E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 Ipf1 17 2.22E-09 Cdc5 8 4.09E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Poxp1 8 4.57E-05 p53 43 1.01E-17 Creb1 17 4.29E-09 Ipf1 8 4.57E-05 Down Primaries ≥4h	Myc (2)	140	1.99E-43	Pax4	47	1.68E-13	Pax4	22	4.59E-07			
E2f (Tfbp2) 64 1.8E-38 Foxí2 37 3.82E-12 Sox9 11 1.75E-06 Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26 2.26E-06 Fox/2 107 1.27E-27 Tcf8 33 2.37E-11 Atf2 8 3.07E-06 Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Foxo4 26 9.92E-06 Ddit3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Fox/2 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05	E2f (13)	65	6.89E-40	Ap4	51	3.29E-13	Maz:Myc	30	7.78E-07			
Pax4 136 2.55E-30 Myod 37 4.47E-12 Nfatc 26 2.26E-06 Foxf2 107 1.27E-27 Tcf8 33 2.37E-11 Atf2 8 3.07E-06 Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Foxo4 26 9.92E-06 Odit3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Foxo42 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 Ipf1 17 2.72E-09 Pax2 8 4.57E-05 <	E2f (Tfbp1)	64	1.8E-38	Maz:Myc	64	6.17E-13	Nfil3	10	8.32E-07			
Foxf2 107 1.27E-27 Tcf8 33 2.37E-11 Atf2 8 3.07E-06 Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Foxo4 26 9.92E-06 Ddit3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Foxf2 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 Ipf1 17 2.72E-09 Pax2 8 4.3E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.5Te-05	E2f (Tfbp2)	64	1.8E-38	Foxf2	37	3.82E-12	Sox9	11	1.75E-06			
Ets2 115 4.64E-26 Myc 38 2.66E-11 Pou2f1 9 8.84E-06 Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Foxo4 26 9.92E-06 Ddit3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Foxf2 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 Ipf1 17 2.72E-09 Pax2 8 4.32E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.57E-05 Down Primaries 24h Factor Genes p-value Factor Sense p-value Factor	Pax4	136	2.55E-30	Myod	37	4.47E-12	Nfatc	26	2.26E-06			
Foxa1 90 8.16E-25 Ets2 38 1.11E-10 Foxo4 26 9.92E-06 Ddit3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Foxf2 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 Ipf1 17 2.72E-09 Pax2 8 4.32E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.57E-05 p53 43 1.01E-17 Creb1 17 4.29E-09 Ipf1 8 4.57E-05 Factor Genes p-value Factor Genes p-value Factor Sp1	Foxf2	107	1.27E-27	Tcf8	33	2.37E-11	Atf2	8	3.07E-06			
Ddit3 (Chop) 50 1.03E-24 Atf3 25 7.25E-10 Foxf2 16 1.34E-05 Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 Ipf1 17 2.72E-09 Pax2 8 4.32E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.57E-05 p53 43 1.01E-17 Creb1 17 4.29E-09 Ipf1 8 4.57E-05 Down Primaries 24h Factor Genes p-value Factor Genes p-value Factor Genes p-value Factor Sp1 4.38E-98 7.29E-45 Ap4 (2) <td>Ets2</td> <td>115</td> <td>4.64E-26</td> <td>Мус</td> <td>38</td> <td>2.66E-11</td> <td>Pou2f1</td> <td>9</td> <td>8.84E-06</td>	Ets2	115	4.64E-26	Мус	38	2.66E-11	Pou2f1	9	8.84E-06			
Ap4 134 1.47E-22 Zfp161 17 7.56E-10 Ets2 17 2.75E-05 Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 lpf1 17 2.72E-09 Pax2 8 4.32E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.57E-05 p53 13 1.01E-17 Creb1 17 4.29E-09 lpf1 8 4.57E-05 Down Vrimaries 24h Factor Genes p-value Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38	Foxa1	90	8.16E-25	Ets2	38	1.11E-10	Foxo4	26	9.92E-06			
Sox9 59 1.1E-21 Foxa1 29 1.50E-09 Gata1 8 3.00E-05 Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 lpf1 17 2.72E-09 Pax2 8 4.32E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.57E-05 p53 43 1.01E-17 Creb1 17 4.29E-09 lpf1 8 4.57E-05 Factor Genes p-value Factor Genes p-value Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 7 5.4E-22 Sp1 262 7.34E-61 Nfatc 108 3.6E-31	Ddit3 (Chop)	50	1.03E-24	Atf3	25	7.25E-10	Foxf2	16	1.34E-05			
Ap1 107 8.36E-21 E4f1 27 2.22E-09 Cdc5 8 4.09E-05 CEBPa 50 1.03E-24 lpf1 17 2.72E-09 Pax2 8 4.32E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.57E-05 Down Primaries ≥4h Down C2C12 24h + SB Down C2C12 24h + SB Down C2C12 48h + SB Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	Ap4	134	1.47E-22	Zfp161	17	7.56E-10	Ets2	17	2.75E-05			
CEBPa 50 1.03E-24 lpf1 17 2.72E-09 Pax2 8 4.32E-05 MyoD 94 2.93E-20 Runx1 17 2.88E-09 Pcbp1 8 4.57E-05 p53 43 1.01E-17 Creb1 17 4.29E-09 lpf1 8 4.57E-05 Down Primaries ≥4h Down C2C12 24h + SB Down C2C12 48h + SB Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	Sox9	59	1.1E-21	Foxa1	29	1.50E-09	Gata1	8	3.00E-05			
MyoD p53 94 2.93E-20 p53 Runx1 Runx1 17 2.88E-09 p59 Pcbp1 p59 8 4.57E-05 Down Primaries ≥4h Down C≥C12 24h + SB Down C≥C12 24h + SB Down C≥C12 48h + SB Factor Genes p-value Factor Genes p-value Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	Ap1	107	8.36E-21	E4f1	27	2.22E-09	Cdc5	8	4.09E-05			
p53 43 1.01E-17 Creb1 17 4.29E-09 lpf1 8 4.57E-05 Down Primaries ≥4h Down C2C12 24h + SB Down C2C12 48h + SB Factor Genes p-value Factor Genes p-value Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	CEBPa	50	1.03E-24	lpf1	17	2.72E-09	Pax2	8	4.32E-05			
Down Primaries ≥4h Down C2C12 24h + SB Down C2C12 24h + SB Down C2C12 48h + SB Factor Genes p-value Factor Genes p-value Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	MyoD	94	2.93E-20	Runx1	17	2.88E-09	Pcbp1	8	4.57E-05			
Factor Genes p-value Factor Genes p-value Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	p53	43	1.01E-17	Creb1	17	4.29E-09	lpf1	8	4.57E-05			
Factor Genes p-value Factor Genes p-value Factor Genes p-value Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	Down	Drimariae '	2/h	Down C	2C12 2/lb	. CB	Down C2C12 48h + SP					
Ap4 (3) 231 4.38E-98 Tcf3 147 7.9E-45 Ap4 (2) 58 1.1E-24 Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19												
Tcf3 (E12) (2) 276 1.44E-85 Maz:Myc 130 7.2E-38 Sp1 76 5.4E-22 Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19												
Foxo4 216 1.67E-61 Sp1 149 1.3E-37 Nfatc 58 4.2E-20 Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19												
Sp1 262 7.34E-61 Nfatc 108 3.6E-31 Maz:Myc 62 5.2E-19	, , , ,			,								
The state of the s												
	Mef2 (6)	124	6.84E-60	Ap1 (3)	80	1.8E-29	Lef1 (2)	57	1.2E-18			

93

4.9E-29

Tcf3

	Myod (3)	137	3.61E-56	Foxo4	103	3.1E-25	Pax4	45	9.1E-18
	Lef1 (2)	196	5.56E-52	Pax4	79	1E-24	Srf	20	4.7E-16
	Nfatc	184	3.32E-47	Lef1 (2)	96	1E-22	Ap1	39	1.6E-15
	Meis1	113	8.85E-43	Ets2	67	2.4E-21	Mef2 (2)	29	4.5E-12
	Pax4	138	9.93E-40	Myod	58	6.2E-19	Tead1	22	6.2E-12
	Nf1	99	1.11E-37	Meis1	50	7.9E-16	Tcf8	28	4.5E-10
	Ap1	113	2.13E-30	Mef2a	45	2.2E-15	Evi1	15	3.9E-10
	Vsx1	92	1.05E-28	Foxf2	48	6.7E-13	Foxo4	43	1.1E-09
	Tead1	58	4.87E-25	Tcf8	44	8E-13	Foxf2	27	1.8E-09
	Мус	97	6.1E-24	Мус	51	9.9E-13	Ets2	29	3.6E-09
	Tcf8	47	8.74E-24	Srf	24	1.1E-12	Nf1	23	6.6E-09
	Tbp	43	3.19E-21	Atf1	23	3.1E-12	Ap4	13	1.8E-08
	Ap4	42	1.1E-19	Nf1	40	9.8E-12	Meis1	24	1.8E-08
	Srf	38	1.33E-18	Err1	49	1.7E-11	Myod	25	3.6E-08
F: 3 T-1-1	<u> </u>								

Ap4 (2)

Fig. 3 Table showing transcription factor binding sites of p38a-regulated genes. Analyses of DNA-binding elements present in promoters were performed using GSEA. Red numbers indicate number of times that the factor appeared in the analysis with different DNA-binding elements, the highest P value element is shown. Unknown binding elements have been omitted

organization, and serine/threonine and protein kinaserelated genes; genes bound only in proliferative conditions were enriched in Golgi apparatus genes, positive regulators of transcription and further enriched in Wnt signaling molecules. Interestingly, genes bound only in differentiating conditions were enriched in glycoproteins and membrane proteins, and in general, but negative regulators of transcription (positive general transcriptional regulators were not enriched) (Fig. 4c). Moreover, GSEA analysis of transcription factor binding sites in the p38α-bound genes identified enriched binding sites for nearly the same transcription factors found in p38α-regulated genes obtained in the expression microarrays, for example: Sp1, Lef1, Tcf3/E47, FoxO4, Pax4, MyoD, or Nfatc

220

1.34E-56

Maz:Myc

(Fig. 4d). Since some of these transcription factors have been described as phosphorylation substrates of p38 MAPK in different model systems, including Sp1 [32, 33] Tcf3/E47 [12], NFATC4 [34], or E2F4 [35], and the pattern of p38 α recruitment to genes is mostly restricted to proximal promoter regions, it is tempting to propose that p38α will likely regulate the myoblast proliferation-to-differentiation transition mainly through these transcription factors.

63

9E-18

Of note, genome-wide binding analysis of p38α in experimental conditions of myogenic differentiation, where p38α is expressed but its kinase activity is inhibited (C2C12 cells in DM + SB), revealed that the kinase activity was not required for p38α recruitment to chromatin; on the contrary, at the genome level, there was a generally increased occupancy

Page 9 of 15




Fig. 4 ChIP-on-chip analysis for p38α in myogenic cells. Chromatin immunoprecipitation (ChIP) was performed in C2C12 myoblasts (under different culture conditions) using a p38α-specific antibody. **a** Non-proportional 2-way Venn diagram showing the number of promoters bound by p38α in the two experimental conditions: proliferation (GM) and 24 h of differentiation (24 h DM). **b** Clustering analysis of genes bound by p38α in GM and 24 h DM. Genes were grouped in five clusters according to the pattern of binding along the promoter. Cluster 1 is enriched in transcription factors, developmental regulators, and muscle-related genes. Cluster 2 is enriched in genes involved in bone development, developmental regulators, and transcription factors and cluster 3 includes miscellaneous genes. Cluster 4 is enriched in sensory perception and olfactory receptors whereas cluster 5 is enriched in protein transport, phosphorylation, and cell cycle-related genes. **c** Functional annotation analysis of the Gene ontology (GO) of bound genes in GM and 24 h DM was performed using DAVID. The top annotation clusters are shown according to their enrichment score. Names are based on enriched GO annotations. **d** Table showing transcription factor binding sites of p38α-bound genes. Analyses of DNA-binding elements present in promoters were performed using GSEA. The highest *P* value element is shown. Unknown binding elements have been omitted

signal on promoters when cells were treated with the $p38\alpha/\beta$ inhibitor, as exemplified by full chromosome 11 and the promoter of Wnt9a, one of the $p38\alpha$ -regulated genes (Fig. 5). This indicates that recruitment of $p38\alpha$ to certain gene promoters is independent of its kinase activity, although the underlying reason is currently unknown.

Identification of genes bound and regulated by $p38\alpha$ during early myogenic differentiation

To complete the identification of the genes bound and regulated by $p38\alpha$ at the myogenic proliferation-to-differentiation switch, we crossed the two data sets: the expression microarray and the ChIP-on-chip data. We

Page 10 of 15




Fig. 5 The kinase activity is not required for p38α recruitment to chromatin. p38α-bound promoters in full chromosome 11 and the promoter of Wnt9a, one of the p38α-regulated genes, as an example of the general increased occupancy signal observed on promoters when cells were treated with the SB203580 p38α/β inhibitor. UCSC genome browser with overimposed binding signal is shown

identified 46 genes bound by p38α that were upregulated in SB-treated C2C12 myoblasts, and 70 genes bound and downregulated in similar C2C12 cell culture conditions. Of these, only 10 and 12 genes were also up- and downregulated, respectively, in p38α-deficient satellite cells (Fig. 6a, b). Furthermore, GO analysis of the genes bound and regulated by p38α in differentiating C2C12 cells showed that they are mainly involved in signal transduction pathways, response to hypoxia, homeostatic processes, and cell proliferation. On the other hand, GO analysis of genes bound by p38α and upregulated when p38α activity was chemically inhibited showed enrichment for transcription factors and nuclear receptor coactivators (Fig. 6c). Interestingly, DAVID analysis of canonical pathways enriched in genes bound by p38α highlighted the Wnt signaling pathway as the main signaling module regulated by p38α (Fig. 6d).

We validated p38 α binding to the promoters of genes up- or downregulated after p38 inactivation in myogenic cells belonging to the different GO categories and pathways described above: Wnt signaling pathway (Wnt9a), actin cytoskeleton organization (Dock1), cellular signaling (RhoU, Kitl and Skil), and regulation of transcription (Spry1). This validation was performed through ChIP of cells cultured in three different conditions (GM, 24, and

48 h DM—this latter time-point was included to extend the kinetics of p38 α binding), and subsequent semiquantitative or qPCR analysis of the immunopurified DNA (Fig. 7a, b). Moreover, and consistent with previously published results [15, 21], we found that p38 α recruitment to Myog and Pax7 promoters is increased upon differentiation (Fig. 7c). Of note, actual recruitment of the muscle regulatory factor MyoD (but not Mef2) to the newly identified p38 α targets Wnt9a and RhoU in differentiating C2C12 myoblasts was confirmed by ChIP-qPCR (Fig. 7d, e).

Discussion

During myogenesis, satellite cells need to cease proliferation and initiate differentiation as a key step to fuse and form multinucleated myotubes. In vivo, this is the central step for the success of the tissue regeneration process in response to injury (i.e., forming new myofibers to repair the damaged muscle tissue). Previous studies had shown that the proliferation-to-differentiation transition of myoblasts (derived from satellite cells or from immortalized myogenic cell lines) requires timely activation of p38 α MAPK (reviewed in [3, 4, 7, 9]), being this isoform also needed for proper muscle regeneration in mice [25]. Interestingly, this isoform was also shown to play an important role in muscular dystrophy progression




Fig. 6 Identification of genes bound and regulated by p38α. **a, b** The two data sets (expression array and ChIP-on-chip) were crossed to identify genes bound and regulated by p38α. The non-proportional 2-way Venn diagrams show that, at 24 h of differentiation (DM), p38α binds to the promoter of 46 genes upregulated in SB-treated C2C12 cells (**a**) and to 70 genes downregulated in myoblasts lacking active p38α (**b**). Only 10 and 12 of these bound genes are also upregulated and downregulated, respectively, in p38α-deficient satellite cells. **c** Gene ontology analysis of genes bound and regulated by p38α in C2C12 cells at 24 h in DM. Enriched GO annotations of genes downregulated in SB-treated C2C12 myoblasts are shown in green whereas enriched GO annotations of upregulated genes are shown in red. **d** DAVID analysis of canonical pathways enriched in genes bound by p38α showed that Wnt signaling pathway was one of the main signaling modules regulated by p38α. KEGG pathway is shown with p38α-bound promoters highlighted

in mice [36]. Here, we show that $p38\alpha$ exerts this myogenic function at least in part via binding and acting at chromatin. By genome-wide localization analysis coupled to gene expression profiling, we found this p38 isoform

associated with mammalian loci more frequently than in any study previously published. In particular, $p38\alpha$ associated with chromatin during the myoblast proliferation-to-differentiation transition, and this correlated with the high




Fig. 7 Validation of p38α binding at several identified targets. **a** Proliferating (GM) or differentiating (24 and 48 h DM) C2C12 cells were subjected to ChIP analysis with antibodies to p38α or control rabbit IgG. Immunopurified DNA was subjected to semiquantitative PCR with indicated primers, and the PCR products were then run on an agarose gel. Representative images are shown. Densitometry of the bands was measured using ImageJ and normalized to input. **b**, **c** DNA from C2C12 cells was immunopurified as in (**a**) and then subjected to qPCR analysis with indicated primers. Data show the relative recruitment of p38α at these promoters and represent the mean of three independent experiments ± SEM. Non-parametric Mann–Whitney *U* test was used to assess statistical significance (*P* value <0.05). **d**, **e** Proliferating (GM) or differentiating (24 and 48 h DM) C2C12 cells were subjected to ChIP analysis with antibodies to MyoD, Mef2 or control rabbit IgG and immunopurified DNA was subjected to qPCR analysis with indicated primers

levels of transcription, supporting the relevance of kinase signaling pathways in directly regulating transcription, in agreement with previous reports [37–40]. At variance with the classical view of p38 α as a positive regulator of transcription [12, 41], we also found that the p38 α -

chromatin binding was not always associated with active transcription during this myogenic transition, since many p38 α -bound promoters were transcriptionally inactive or repressed. Thus, p38 α is recruited to a large set of myogenic gene promoters to facilitate their activation

Page 13 of 15

or repression, hence pointing to more complex regulatory mechanisms than previously anticipated.

How is p38α recruited to muscle loci is not known, but it likely involves interaction with chromatinregulatory and/or transcription factors, as demonstrated for several stress-induced genes [42]. Of interest, p38αbound promoters are enriched with binding motifs for several transcription factors, principally Sp1, Tcf3/E47, Lef1, FoxO4, MyoD, and NFATc, which are known to be phosphorylation substrates of p38 MAPK. In skeletal myoblasts, in particular, p38α associates with MyoD and E47 [12, 15] transcription factors, and specific phosphorylation of E47 promotes E47/MyoD dimerization, binding to muscle-specific loci and initiation of gene expression [12]. Likewise, phosphorylation of MEF2 by p38 facilitates both recruitment of MyoD and expression of late myogenic genes, in a feed-forward mechanism [11], and of ASH2L-MLL methyltransferase complex [18, 19]. p38α also phosphorylates Baf60c allowing SWI/SNF-mediated chromatin remodeling at musclespecific loci [15–17]. Interestingly, p38α was also shown to represses Pax7 gene expression via direct Ezh2 phosphorylation, as an indispensable event for the transition of proliferating myoblasts into their differentiating state [21]. Thus, p38α may help both silence proliferation-associated genes and activate differentiation-promoting genes at this transition, by directly targeting negative and positive epigenetic and/or transcriptional regulators. Because the p38 MAPK homolog Hog1 targets the RNA Pol II machinery and induces chromatin remodeling at stress-responsive loci in yeast [43], it is possible that p38α regulates Pol IIdependent gene transcription in mammalian myogenesis in a similar way. It is worth noting that p38 was also found on a subset of genes independently of its kinase activity. Our work adds to several recent studies of protein kinases that bind and act on chromatin: extracellular signal-regulated kinase (ERK), cJun Nterminal kinase (JNK), the MSK, AMPK, and Dyrk1A [37, 38, 44-46]. This study also complements the previously described association of p38/Hog1 to osmostress genes to mediate adaptation to extracellular changes in mammals and yeast [26, 27, 42].

Of interest, we observed slower muscle differentiation kinetics in C2C12 myoblasts compared to satellite cells in culture; although the underlying causes for this difference are not clear, they may relate to the distinct nature of both cell types (freshly isolated cells versus immortalized cells) and the different velocity of p38 α activation in both cell types (see Fig. 1a). Whether the expression of the identified p38 α -regulated late genes depends on the early ones, according to the proposed temporal regulation of muscle gene expression through a MyoD-mediated feed-forward circuit involving p38 MAPK [11], is not yet known.

Finally, although the nature of p38α-regulated genes encompasses several categories, DAVID analysis of canonical pathways enriched in genes bound by p38α showed the Wnt pathway as the main signaling module regulated by p38α. Consistent with this, MyoD was found to be recruited to the newly identified p38α target Wnt9a, in addition to muscle-specific gene promoters, as expected. This is worth highlighting based on the reported relevant role of canonical and non-canonical Wnt signaling in distinct satellite cell functions in vivo (expansion, switching from proliferation to differentiation or cell motility) [47-49]. Taken together, this study increases our understanding on how p38 MAPK regulates gene expression during myogenesis, and greatly enlarges the number and nature of target genes downstream of p38α activation. Notably, through this analysis, we have become aware of new categories of genes whose repression depends on p38α both in proliferating and differentiating conditions, expanding, yet complicating, the function of p38α as a negative regulator of muscle gene transcription. It is possible that comparable principles of chromatin binding and activity might be relevant for other kinases.

Conclusions

Collectively, through this study, we demonstrate association and action of p38 α MAPK throughout chromatin uncovering new classes of target genes during the transition of myoblasts from proliferation to differentiation. The recruitment of p38 α to large sets of gene promoters appears to facilitate their activation or repression during this process. This is consistent with this MAPK isoform being a transcriptional regulator.

Additional files

Additional file 1: Table S2. List of primers used in the study. (XLSX 12 kb) **Additional file 2: Table S1.** List of genes regulated and bound by p38a. (XLSX 686 kb)

Additional file 3: Supplementary Figures 1 and 2 and legends. Figure S1. Relative expression of p38α and p38β in C2C12 cells. The expression of p38α and p38β was measured by qPCR in differentiating C2C12 cells. Values are mean \pm SEM of three independent set of samples. Figure S2. Nuclear p38α remains constant in proliferating and differentiating myoblasts. Expression of p38α in C2C12 cells in GM and 24 h in DM: p38α (green) and DAPI (blue). Nuclear to cytoplasm fluorescence ratio was calculated using integrated density values in ImageJ software with DAPI as nuclear boundary. Scale bar = 25 μm. (PDF 7595 kb)

Abbreviations

BAF60c: BRG1/BRM-associated factor 60 variant c; ChIP: chromatin immunoprecipitation; DAPI: 4',6-diamidino-2-phenylindole; DM: differentiation medium; Dock1: dedicator of cytokinesis; FoxO4: forkhead box protein O4; GM: growth medium; GO: gene ontology; GSEA: gene set enrichment analysis; Lef1: lymphoid enhancer-binding factor 1; MAPK: mitogen-activated protein kinase; MEF2: myocyte enhancer factor 2; MRFs: myogenic regulatory factors; NFATc: nuclear factor of activated T cells; Pax4: paired box gene 4; RT-qPCR: reverse transcriptase quantitative

Page 14 of 15

polymerase chain reaction; Spry1: protein sprouty homolog 1; Tcf3: transcription factor 3 (E2A immunoglobulin enhancer-binding factors E12/E47); Wnt9a: wingless-type MMTV integration site family, member 9A; WT: wild type.

Competing interests

The authors declared that they have no competing interests.

Authors' contributions

JS designed and performed experiments, analyzed data, and interpreted results and wrote the manuscript. ABMMK performed bioinformatic analysis and edited the manuscript. RK performed bioinformatic analysis and edited the manuscript. QL performed experiments. PS-V performed experiments. FJD performed experiments, analyzed data, and interpreted results. EB performed ChIP experiments and edited the manuscript. EP designed and performed experiments, analyzed data, and interpreted results and wrote the manuscript. PMC conceived the project, designed experiments, interpreted results, and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Drs. V. Ruiz-Bonilla, M. Jardí, and M. Raya, for their help and contribution to this study. The CRG/UPF Genomic Unit for excellent support. The authors acknowledge funding from MINECO, Spain (SAF2012-38547, PLE2009-0124, SAF2015-67369-R, "María de Maeztu" Programme for Units of Excellence in R&D MDM-2014-0370), AFM, MDA, DDP-Netherlands, E-RARE, Fundació Marató TV3 and EU-FP7 (Myoage, Optistem and Endostem). JS is recipient of a Juan de la Cierva postdoctoral fellowship.

Author details

¹Department of Experimental and Health Sciences, Pompeu Fabra University (UPF), CIBER on Neurodegenerative diseases (CIBERNED), Barcelona, Spain. ²Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka 1000, Bangladesh. ³Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA. ⁴Sprott Center for Stem Cell Research, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada. ⁵Chromatin and Disease Group, Cancer Epigenetics and Biology Programme (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. ⁶Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. ⁷Present address: Buck Institute for Research on Aging, Novato, CA, USA.

Received: 11 September 2015 Accepted: 5 January 2016 Published online: 15 March 2016

References

- Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007;1773(8):1358–75. doi:10.1016/j.bbamcr.2007.03.010.
- Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403–17. doi:10.1042/BJ20100323.
- Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 2006;16(1):36–44. doi:10.1016/j.tcb.2005.11.002.
- Keren A, Tamir Y, Bengal E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Mol Cell Endocrinol. 2006;252(1-2):224–30. doi:10.1016/j.mce.2006.03.017.
- Mahmoudi S, Brunet A. Aging and reprogramming: a two-way street. Curr Opin Cell Biol. 2012;24(6):744–56. doi:10.1016/j.ceb.2012.10.004.
- Neves J, Demaria M, Campisi J, Jasper H. Of flies, mice, and men: evolutionarily conserved tissue damage responses and aging. Dev Cell. 2015;32(1):9–18. doi:10.1016/j.devcel.2014.11.028.
- Perdiguero E, Ruiz-Bonilla V, Gresh L, Hui L, Ballestar E, Sousa-Victor P, et al. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J. 2007;26(5):1245–56.
- Mourikis P, Tajbakhsh S. Distinct contextual roles for Notch signalling in skeletal muscle stem cells. BMC Dev Biol. 2014;14:2. doi:10.1186/1471-213X-14-2.
- Vahidi Ferdousi L, Rocheteau P, Chayot R, Montagne B, Chaker Z, Flamant P, et al. More efficient repair of DNA double-strand breaks in skeletal muscle stem cells compared to their committed progeny. Stem Cell Res. 2014;13(3 Pt A):492–507. doi:10.1016/j.scr.2014.08.005.

- Zhao M, New L, Kravchenko W, Kato Y, Gram H, Di Padova F, et al. Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol. 1999;19(1):21–30.
- Penn BH, Bergstrom DA, Dilworth FJ, Bengal E, Tapscott SJ. A MyoDgenerated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation. Genes Dev. 2004;18(19):2348–53.
- Lluis F, Ballestar E, Suelves M, Esteller M, Munoz-Canoves P. E47 phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle-specific gene transcription. EMBO J. 2005;24(5):974–84. doi:10.1038/sj.emboj.7600528.
- 13. Perdiguero E, Sousa-Victor P, Ballestar E, Munoz-Canoves P. Epigenetic regulation of myogenesis. Epigenetics. 2009;4(8):541–50.
- Fulle S, Di Donna S, Puglielli C, Pietrangelo T, Beccafico S, Bellomo R, et al. Age-dependent imbalance of the antioxidative system in human satellite cells. Exp Gerontol. 2005;40(3):189–97. doi:10.1016/j.exger.2004. 11.006
- Simone C, Forcales SV, Hill DA, Imbalzano AN, Latella L, Puri PL. p38 pathway targets SWI-SNF chromatin-remodeling complex to muscle-specific loci. Nat Genet. 2004;36(7):738–43. doi:10.1038/ng1378ng1378.
- Serra C, Palacios D, Mozzetta C, Forcales SV, Morantte I, Ripani M, et al. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell. 2007;28(2):200–13. doi:10.1016/j.molcel.2007.08.021.
- Forcales SV, Albini S, Giordani L, Malecova B, Cignolo L, Chernov A, et al. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. EMBO J. 2012;31(2):301–16. doi:10.1038/emboj.2011.391.
- Rampalli S, Li L, Mak E, Ge K, Brand M, Tapscott SJ, et al. p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation. Nat Struct Mol Biol. 2007;14(12):1150–6. doi:10.1038/nsmb1316.
- Brack AS, Bildsoe H, Hughes SM. Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. J Cell Sci. 2005;118(Pt 20):4813–21. doi:10.1242/jcs.02602.
- Cuadrado A, Corrado N, Perdiguero E, Lafarga V, Munoz-Canoves P, Nebreda AR. Essential role of p18(Hamlet)/SRCAP-mediated histone H2A.Z chromatin incorporation in muscle differentiation. EMBO J. 2010. doi:10.1038/emboj.2010.85.
- Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, et al. TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell. 2010;7(4):455–69. doi:10.1016/j.stem.2010.08.013.
- Gillespie MA, Le Grand F, Scime A, Kuang S, von Maltzahn J, Seale V, et al. p38-{gamma}-dependent gene silencing restricts entry into the myogenic differentiation program. J Cell Biol. 2009;187(7):991–1005. doi:10.1083/jcb.200907037.
- Ruiz-Bonilla V, Perdiguero E, Gresh L, Serrano AL, Zamora M, Sousa-Victor P, et al. Efficient adult skeletal muscle regeneration in mice deficient in p38beta, p38gamma and p38delta MAP kinases. Cell Cycle. 2008;7(14):2208–14.
- Wang H, Xu Q, Xiao F, Jiang Y, Wu Z. Involvement of the p38 mitogen-activated protein kinase alpha, beta, and gamma isoforms in myogenic differentiation. Mol Biol Cell. 2008;19(4):1519–28. doi:10.1091/mbc.E07-08-0817.
- Brien P, Pugazhendhi D, Woodhouse S, Oxley D, Pell JM. p38alpha MAPK regulates adult muscle stem cell fate by restricting progenitor proliferation during postnatal growth and repair. Stem Cells. 2013;31(8):1597–610. doi:10.1002/stem.1399.
- De Nadal E, Zapater M, Alepuz PM, Sumoy L, Mas G, Posas F. The MAPK Hog1 recruits Rpd3 histone deacetylase to activate osmoresponsive genes. Nature. 2004;427(6972):370–4. doi:10.1038/nature02258.
- Pokholok DK, Zeitlinger J, Hannett NM, Reynolds DB, Young RA. Activated signal transduction kinases frequently occupy target genes. Science. 2006;31(5786):533–6. doi:10.1126/science.1127677.
- 28. Ferreiro I, Barragan M, Gubern A, Ballestar E, Joaquin M, Posas F. The p38 SAPK is recruited to chromatin via its interaction with transcription factors. J Biol Chem. 2010;285(41):31819–28. doi:10.1074/jbc.M110.155846.
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80. doi:10.1186/gb-2004-5-10-r80.
- da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211.

- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. doi:10.1073/pnas.0506580102.
- D'Addario M, Arora PD, McCulloch CA. Role of p38 in stress activation of Sp1. Gene. 2006;379:51–61. doi:10.1016/j.gene.2006.04.012.
- Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res. 2007;67(13):6121–9. doi:10.1158/0008-5472.CAN-07-0141.
- Yang TT, Xiong Q, Enslen H, Davis RJ, Chow CW. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol Cell Biol. 2002;22(11):3892–904.
- Morillo SM, Abanto EP, Roman MJ, Frade JM. Nerve growth factorinduced cell cycle reentry in newborn neurons is triggered by p38MAPK-dependent E2F4 phosphorylation. Mol Cell Biol. 2012;32(14):2722–37. doi:10.1128/MCB.00239-12.
- Wissing ER, Boyer JG, Kwong JQ, Sargent MA, Karch J, McNally EM, et al. P38alpha MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism. Hum Mol Genet. 2014;23(20):5452–63. doi:10.1093/hmq/ddu270.
- Tiwari VK, Stadler MB, Wirbelauer C, Paro R, Schubeler D, Beisel C. A chromatin-modifying function of JNK during stem cell differentiation. Nat Genet. 2011;44(1):94–100. doi:10.1038/ng.1036.
- Vicent GP, Ballare C, Nacht AS, Clausell J, Subtil-Rodriguez A, Quiles I, et al. Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. Mol Cell. 2006;24(3):367–81. doi:10.1016/j.molcel.2006.10.011.
- Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B, et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science. 2010;329(5996):1201–5. doi:10.1126/science.1191241.
- Di Vona C, Bezdan D, Islam AB, Salichs E, Lopez-Bigas N, Ossowski S, et al. Chromatin-wide profiling of DYRK1A reveals a role as a genespecific RNA polymerase II CTD kinase. Mol Cell. 2015;57(3):506–20. doi:10.1016/j.molcel.2014.12.026.
- Putker M, Madl T, Vos HR, de Ruiter H, Visscher M, van den Berg MC, et al. Redox-dependent control of FOXO/DAF-16 by transportin-1. Mol Cell. 2013;49(4):730–42. doi:10.1016/j.molcel.2012.12.014.
- Rezza A, Sennett R, Rendl M. Adult stem cell niches: cellular and molecular components. Curr Top Dev Biol. 2014;107:333–72. doi:10.1016/B978-0-12-416022-4.00012-3.
- Nadal-Ribelles M, Conde N, Flores O, Gonzalez-Vallinas J, Eyras E, Orozco M, et al. Hog1 bypasses stress-mediated down-regulation of transcription by RNA polymerase II redistribution and chromatin remodeling. Genome Biol. 2012;13(11):R106. doi:10.1186/gb-2012-13-11-r106.
- Aurora AB, Olson EN. Immune modulation of stem cells and regeneration. Cell Stem Cell. 2014;15(1):14–25. doi:10.1016/j.stem.2014.06.009.
- Murphy MM, Keefe AC, Lawson JA, Flygare SD, Yandell M, Kardon G. Transiently active Wnt/beta-catenin signaling is not required but must be silenced for stem cell function during muscle regeneration. Stem Cell Rep. 2014;3(3):475–88. doi:10.1016/j.stemcr.2014.06.019.
- Lawrence MC, McGlynn K, Shao C, Duan L, Naziruddin B, Levy MF, et al. Chromatin-bound mitogen-activated protein kinases transmit dynamic signals in transcription complexes in beta-cells. Proc Natl Acad Sci U S A. 2008;105(36):13315–20. doi:10.1073/pnas.0806465105.
- Le Grand F, Jones AE, Seale V, Scime A, Rudnicki MA. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell. 2009;4(6):535–47. doi:10.1016/j.stem.2009.03.013.
- Tanaka S, Terada K, Nohno T. Canonical Wnt signaling is involved in switching from cell proliferation to myogenic differentiation of mouse myoblast cells. J Mol Signal. 2011;6:12. doi:10.1186/1750-2187-6-12.
- Bentzinger CF, von Maltzahn J, Dumont NA, Stark DA, Wang YX, Nhan K, et al. Wnt7a stimulates myogenic stem cell motility and engraftment resulting in improved muscle strength. J Cell Biol. 2014;205(1):97–111. doi:10.1083/jcb.201310035.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

